Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

EntreMed Files for China Arm of its Sarcoma Clinical Trial

publication date: Jun 27, 2013
EntreMed, a US pharma with a Beijing subsidiary, has filed an application with the CFDA to conduct a clinical trial in China for ENMD-2076, a novel drug that is EntreMed’s lead drug candidate. Currently, the drug is undergoing a Phase II trial at Toronto’s Princess Margaret Hospital for advanced/metastatic sarcoma. EntreMed wants to expand its effort into a global trial to implement its plans for integrated development of the drug. More details....

Stock Symbol: (NSDQ: ENMD)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital